REGN:
The current market price is 377.1, showing no change from the previous close.
Support and Resistance Levels
The support levels are 375.0, 373.0, and 370.0. Resistance levels are 380.0, 385.0, and 390.0. The pivot point is 377.5.
Indicators
The RSI is at 100, indicating extreme overbought conditions. The ATR is 0, showing low volatility. Parabolic SAR is at 377.1, suggesting no trend reversal.
Market Sentiment
The market is bullish as the price is above the pivot point of 377.5, with RSI supporting a buying trend.
REGN Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company headquartered in Tarrytown, New York. Founded in 1988, Regeneron specializes in discovering, developing, and commercializing innovative medicines for the treatment of serious diseases. The company is renowned for its commitment to scientific excellence and has established a robust pipeline of biologics and small-molecule drugs. Regeneron's core areas of focus include ophthalmology, oncology, immunology, and cardiovascular diseases, fostering a diversified portfolio that addresses significant unmet medical needs.
Market Position
Regeneron is recognized as one of the prominent players in the biotech industry, with a strong market presence driven by its advanced research capabilities and successful product launches. The company's flagship products, such as EYLEA (aflibercept) for eye diseases and Dupixent (dupilumab) for various allergic and inflammatory conditions, have significantly contributed to its revenue streams. Regeneron's competitive advantage lies in its proprietary VelociSuite® technology platform, which accelerates the discovery of new therapeutic candidates, ensuring the company remains at the forefront of innovation in the pharmaceutical sector.
Key Financial Highlights
Regeneron's financial performance reflects its strong market position and effective operational strategies. As of the most recent fiscal year, the company reported impressive revenue growth, driven by the robust sales of its existing therapeutics and the advancement of its pipeline products. The company has consistently delivered positive earnings results, translating to a strong return on investment for shareholders. Furthermore, Regeneron maintains a solid balance sheet, providing it with the flexibility to invest in research and development, explore strategic partnerships, and pursue acquisitions that enhance its therapeutic offerings.
Industry Highlights
The biotechnology industry continues to evolve, with Regeneron playing a pivotal role in addressing critical healthcare challenges. The global demand for innovative therapies is increasing, driven by an aging population and the rising prevalence of chronic diseases. As Regeneron expands its pipeline and enhances its R&D capabilities, it is poised to capitalize on emerging market trends and maintain its leadership position within the biotechnology landscape.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
